We are thrilled to be exhibiting at the SITC Conference 2026 from November 5th - 8th in Phoenix, AZ. Visit us at Booth #1020 to explore our AI-powered antibody discovery platform, next-generation immuno-oncology assets and target-humanized and immune-reconstituted mouse models supporting in vivo efficacy and safety evaluation of ADCs, T-cell engagers and other cancer immunotherapies.
What is SITC 2026?
The SITC (Society for Immunotherapy of Cancer) Conference is an annual event that connects foundational research with emerging clinical applications to advance breakthroughs in cancer immunotherapy .The program will examine the latest research and clinical advances and feature scientific presentations, keynote lectures, workshops, roundtables, and more. This is a fantastic opportunity to stay up to date on industry trends and collaborate with researchers, clinicians, and industry leaders.
Event Overview
Date: November 5th - 8th, 2026
Venue: Phoenix Convention Center, 100 N 3rd St, Phoenix, AZ 85004
Booth: 1020
Posters:
The B-NDG hCRBN Humanized Mouse Model Enables in vivo Evaluation of CRBN-based Targeted Protein Degraders and Molecular Glue Therapeutics
Preclinical Evaluation of in vivo CAR-T Therapies Using Human PBMC and HSC Reconstituted Mouse Models in Biocytogen
A Novel CDH17/HER3 Bispecific ADC Demonstrates Superior Preclinical Efficacy in Colorectal Cancer
A Novel CDH17-Targeting CD3xCD28 Trispecific T-Cell Engager Demonstrates Potent Anti-Tumor Activity against Colorectal Cancer in Preclinical Models
Dual-Background Humanized EGFR Mouse Models Enable Preclinical Safety Assessment of EGFR-Targeted Antibodies and Antibody–Drug Conjugates
BCG051: A First-in-Class Bispecific Antibody Targeting GDF-15 and VEGFA to Synergistically Inhibit Tumor Growth and Reverse Cancer-Associated Cachexia
BCG040, a Novel B7-H4-Targeting Biparatopic ADC, Demonstrates Superior Preclinical Efficacy in Heterogeneous Tumors
Preclinical Study of BCG039, a Nectin-4×TROP2 Bispecific ADC, in Urothelial Carcinoma and Other Solid Tumor Models
Employing Humanized CD3EDG/FOLR1/FOLR2 Mice in Non-Clinical Studies of Cancer Immunotherapy
Complementary Humanized and Immunocompetent Mouse Models for Evaluating AMG509 Analog Efficacy and CRS-like Toxicity
Preclinical Efficacy of a CD3×4-1BB×DLL3 Trispecific Antibody in a Novel CD3/4-1BB Dual-Humanized Mouse Model
A Spatially Optimized Long-Acting gp100×CD3×Albumin Trispecific Antibody Enables Durable Antitumor Immunity in gp100-Expressing Solid Tumors
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
